MarketPeel
Insider Trading Intelligence
JG

James R. Gruber

ETON
CHIEF FINANCIAL OFFICER · ETON PHARMACEUTICALS, INC. · CIK 0001923165
FILING MIX · LIFETIME67%/33%
BUYS
8
SELLS
4
TOTAL VALUE
$786.4K
COMPANIES
1
ACTIVE SINCE
Jul 2022
HOLDINGS NOW
213,420
AVG SELL PX
$16.20
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by James R. Gruber, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%+6.09%+1.09%+5.01%+5.01%
14d2+0.00%+5.78%+0.48%+5.30%+5.30%
30d2+0.00%+12.38%+3.76%+8.62%+8.62%
60d2+0.00%+11.70%+4.52%+7.18%+7.18%
90d2+0.00%+5.24%+3.74%+1.49%+1.49%
180d2+0.00%+4.50%+6.78%-2.29%-2.29%
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ETON · 213,420 shares · as of Jan 14, 2026
093,691187,382281,072374,7632023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 8 buys / 4 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ETON
ETON PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,293$15.47$35.5K213,420Jan 14, 2026Jan 14, 2026View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,856279,931Jan 12, 2026Jan 14, 2026View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
40,655254,075Jan 12, 2026Jan 14, 2026View →
ETON
ETON PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
4,542$16.99$77.2K215,713Dec 12, 2025Dec 12, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,502210,255Dec 11, 2025Dec 12, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
2,631$16.02$42.1K204,753Aug 20, 2025Aug 20, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
SALE
Chief Financial Officer
39,082$16.16$631.6K205,299Aug 19, 2025Aug 20, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,87625,876Jan 3, 2025Jan 6, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
38,62138,621Jan 3, 2025Jan 6, 2025View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
144,677374,763Feb 13, 2024Feb 15, 2024View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
100,086200,086Mar 3, 2023Mar 3, 2023View →
ETON
ETON PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
40,00040,000Jul 12, 2022Jul 18, 2022View →
Other insiders · ETON
Loading peer insiders…
About this filer
CIK 0001923165
ROLE
Chief Financial Officer
PRIMARY
ETON
COMPANIES
1
ACTIVE SINCE
Jul 2022
MARKETPEEL · /INSIDER/0001923165DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback